More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$195850853
EPS
-2.1
P/E ratio
--
Price to sales
9.55
Dividend yield
--
Beta
0.075295
Previous close
$13.68
Today's open
$13.60
Day's range
$13.60 - $14.10
52 week range
$11.80 - $19.70
show more
CEO
Ofer Gonen
Employees
121
Headquarters
Yavne,
Exchange
NASDAQ Global Market
Shares outstanding
14390217
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
MediWound to Host Virtual KOL Event on EscharEx ® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 Leading wound care experts to discuss Phase II clinical evidence, the pivotal Phase III VALUE study, and the estimated $1.05 billion U.S. annual peak sales potential YAVNE, Israel, November 16, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, December 2, 2026, at 11:00 a.m.
GlobeNewsWire • Nov 16, 2026

What MediWound (MDWD) Said on Its Q3 Earnings Call
MediWound NASDAQ: MDWD reported lower third-quarter revenue and a wider net loss as it increased spending on its late-stage EscharEx trial, while executives said manufacturing constraints continue to limit sales of its burn treatment NexoBrid.
MarketBeat • Nov 12, 2026

MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript
MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027
GlobeNewsWire • Nov 12, 2026

MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.24 per share a year ago.
Zacks Investment Research • Nov 12, 2026

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the closing of its previously announced underwritten public offering of 1,380,000 ordinary shares, including 180,000 ordinary shares issued pursuant to the full exercise of the underwriter's option to purchase additional ordinary shares, at a public offering price of $12.50 per ordinary share.
GlobeNewsWire • Nov 5, 2026

MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research • Nov 5, 2026

MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C.
GlobeNewsWire • Nov 3, 2026

MediWound to Report Third Quarter 2026 Financial Results
MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd.
GlobeNewsWire • Oct 29, 2026

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
GlobeNewsWire • Sep 22, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MediWound Ltd. commission-free¹. Build wealth for the long term using automated trading and transfers.